Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 4
2005 3
2006 3
2007 6
2008 8
2009 4
2010 8
2011 7
2012 14
2013 13
2014 11
2015 5
2016 3
2017 3
2018 1
2019 6
2020 3
2021 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H. Kato T, et al. Among authors: shimizu n. Int J Urol. 2024 Mar;31(3):265-272. doi: 10.1111/iju.15345. Epub 2023 Dec 18. Int J Urol. 2024. PMID: 38110838
Melatonin is a potential drug for the prevention of bone loss during space flight.
Ikegame M, Hattori A, Tabata MJ, Kitamura KI, Tabuchi Y, Furusawa Y, Maruyama Y, Yamamoto T, Sekiguchi T, Matsuoka R, Hanmoto T, Ikari T, Endo M, Omori K, Nakano M, Yashima S, Ejiri S, Taya T, Nakashima H, Shimizu N, Nakamura M, Kondo T, Hayakawa K, Takasaki I, Kaminishi A, Akatsuka R, Sasayama Y, Nishiuchi T, Nara M, Iseki H, Chowdhury VS, Wada S, Ijiri K, Takeuchi T, Suzuki T, Ando H, Matsuda K, Somei M, Mishima H, Mikuni-Takagaki Y, Funahashi H, Takahashi A, Watanabe Y, Maeda M, Uchida H, Hayashi A, Kambegawa A, Seki A, Yano S, Shimazu T, Suzuki H, Hirayama J, Suzuki N. Ikegame M, et al. Among authors: shimizu n. J Pineal Res. 2019 Oct;67(3):e12594. doi: 10.1111/jpi.12594. Epub 2019 Jul 19. J Pineal Res. 2019. PMID: 31286565 Free PMC article.
Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, Yonese J, Hashine K, Masumori N, Arai G, Saito S, Shinohara M, Shimizu N, Yamauchi A, Satoh T, Tochigi T, Kobayashi M, Fujimoto H, Kakimoto KI, Fukui I, Tsukamoto T, Nozaki M, Karasawa K, Hasumi M, Ohtani M, Ishiyama H, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Naito S, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators. Yokomizo A, et al. Among authors: shimizu n. Cancer Med. 2021 May;10(10):3240-3248. doi: 10.1002/cam4.3895. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932114 Free PMC article. Clinical Trial.
Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K, Saito S, Arai G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Takezawa Y, Fujimoto H, Yokomizo A, Kakimoto KI, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer Investigators. Ito K, et al. Among authors: shimizu n. Cancer. 2020 Sep 1;126(17):3961-3971. doi: 10.1002/cncr.33034. Epub 2020 Jun 23. Cancer. 2020. PMID: 32573779 Free article. Clinical Trial.
Selection of DNA aptamers using atomic force microscopy.
Miyachi Y, Shimizu N, Ogino C, Kondo A. Miyachi Y, et al. Among authors: shimizu n. Nucleic Acids Res. 2010 Mar;38(4):e21. doi: 10.1093/nar/gkp1101. Epub 2009 Dec 2. Nucleic Acids Res. 2010. PMID: 19955232 Free PMC article.
85 results